The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.

In patients with atrial fibrillation for whom vitamin ... the rates of permanent discontinuation of the study medication were 17.9% per year in the apixaban group and 20.5% per year in the aspirin ...

did not receive at least one dose of a trial medication. Apixaban or aspirin was permanently discontinued during follow-up owing to the development of subclinical atrial fibrillation lasting more ...

It appears that apixaban will be an excellent treatment for the many patients with atrial fibrillation who are ... reducing stroke but is a difficult drug to use because of numerous interactions ...

Data sources: EMBASE and MEDLINE were searched (up to June 2012) combining medication names ... Cause in Patients with Atrial Fibrillation/Atrial Flutter AVERROES Apixaban Versus Acetylsalicylic ...

This medication is an anticoagulant, which is used for reducing the risk of strokes and blood clots in patients with atrial fibrillation who have no problems with their heart valve (nonvalvular ...

apixaban in patients with atrial fibrillation despite less bleeding ... “Importantly, that may speak to the dose of the drug used in this study and may speak to how much activity inhibition ...

Those suffering from atrial fibrillation, can now breathe a ... that doctors in England and Wales prescribe a new drug called “apixaban”, which is being marketed under the brand name Eliquis.

The oral anticoagulant medication ... conducted the largest and longest-running study of apixaban for people with device-detected atrial fibrillation. The study involved more than 4,000 ...

The oral anticoagulant medication ... conducted the largest and longest-running study of apixaban for people with device-detected atrial fibrillation. The study involved more than 4,000 ...